ArticleFrontiers in immunology2026
H3K18la facilitates nasopharyngeal carcinoma progression through the activation of the IGF2BP1-COX2 signaling pathway.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor arising from the nasopharyngeal epithelial mucosa, with its development closely associated with metabolic reprogramming. Lactylation, an epigenetic modification induced by lactate, plays a regulatory role in gene transcription.The precise function and mechanisms of H3K18la in NPC malignancy progression are yet to be clarified.This study demonstrates that the glycolytic pathway is markedly activated in NPC tissues, accompanied by elevated expression of H3K18la, which positively correlates with tumour stage. Subsequent studies showed that lactic acid production, mediated by lactate dehydrogenase A (LDHA), facilitates H3K18la modification. Inhibiting LDHA specifically leads to reduced H3K18la levels, suppressed proliferation of NPC cells, and increased apoptosis.H3K18la upregulates the RNA-binding protein IGF2BP1, while inhibiting LDHA or IGF2BP1 reduces COX2 mRNA stability and expression, influencing NPC cell proliferation and apoptosis resistance. In summary, this study indicates that H3K18la modification is crucial for NPC malignancy through the activation of the IGF2BP1-COX2 signaling pathway. This research elucidates lactylation modification mechanisms in NPC, presenting novel targets for its treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.